Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04OTY
|
||||
| Former ID |
DIB001535
|
||||
| Drug Name |
BFH-772
|
||||
| Synonyms |
NVP-BFH-772
|
||||
| Indication | Psoriasis [ICD9: 696; ICD10:L40] | Phase 2 | [1] | ||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | VEGF receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health. | ||||
| REF 2 | CA patent application no. 841416, Method of selecting therapeutic indications. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.